	Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy. Cell Commun Signal Jafari Z, Raoufi A, Athari SS, Bahramkiya S, Jafari D. PMID: 41449459 [PubMed - as supplied by publisher]
	Ultrasound-responsive micro/nanobubbles based intelligent theranostic systems for precision tumor therapy. J Nanobiotechnology Liu D, Ling Y, Liu W, Deng J, Guo Y. PMID: 41449452 [PubMed - as supplied by publisher]
	2D nanomaterial-triggered ferroptosis in cancer therapy. J Nanobiotechnology Gao Y, Xu J, Lai Y, Fan Y, Zhou Y, Tu Y, Liu X, Xia X, Wei GN, Shen JW, Duan W. PMID: 41449419 [PubMed - as supplied by publisher]
	Childhood exposure to second-hand smoke (SHS) and risk of breast cancer in postmenopausal never smokers: the Multiethnic Cohort (MEC) study. Breast Cancer Res Gram IT, Park SY, Wilkens LR, Haiman CA, Wu AH, Le Marchand L. PMID: 41449415 [PubMed - as supplied by publisher]
	Constructing an ultrasound-assisted organoid model for tumor management. Discov Oncol Li T, Wang X, Zhu M, Han S, Zhao D, Wong V, Huang W, Li Z, Zhao H, Qian X. PMID: 41449302 [PubMed - as supplied by publisher]
	Evaluation of INR101, a PSMA-Targeted (18)F PET Tracer, for suspected prostate cancer: A multicenter phase I/IIa trial with histopathologic confirmation. EJNMMI Res Yang J, Wan W, Zhang J, Zhang N, Yang X, Wang W, Ma H, Xu Y, Fu Z, Wang X, Liu Y, Wang M, Liu F, Guo Y, Liu Y, Zhang X. PMID: 41449298 [PubMed - as supplied by publisher]
	Feasibility of Omitting Axillary Dissection after Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence: A Single-Center Retrospective Study. Ann Surg Oncol Nakadaira U, Sakai T, Ogiya A, Inoue Y, Maeda T, Uehiro N, Yamashita N, Kataoka A, Ueno T. PMID: 41449236 [PubMed - as supplied by publisher]
	An update on the role of SMARCA4 deficiency in gynecological neoplasms: how and where. Virchows Arch Maccio L, Bragantini E, Angelico G, Scaglione G, De Leo A, Santoro A, Zannoni GF. PMID: 41449215 [PubMed - as supplied by publisher]
	Prostate cancer diagnosis using sensitive and sophisticated machine learning classifiers based on non-invasive urinary RNA biomarkers (PCASSO). Sci Rep Goh H, Heo T, Kim J, Kim Y, Lim B, Woo MK, Choi KY, Kim CS, Kim J. PMID: 41449174 [PubMed - as supplied by publisher]
	The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply. Lancet Oncol Janssen QP, van Dam JL, Besselink MG, Wilmink JW, Homs MYV, van Tienhoven G, van Eijck CHJ, Groot Koerkamp B. PMID: 41449160 [PubMed - in process]
	Development of a core outcome set for adolescents and young adults with cancer. Lancet Oncol Darlington AS, Way K, Collaço N, Cairns C, Hanebaum S, Janssen SHM, Ko, McCabe MG, Stark D, Sodergren SC, van der Graaf WTA, Husson O, STRONG AYA Consortium. PMID: 41449159 [PubMed - indexed for MEDLINE]
	The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. Lancet Oncol Sherry AD, Jethwa KR, Msaouel P, Ludmir EB. PMID: 41449158 [PubMed - in process]
	International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative. Lancet Oncol Gupta R, Fielder T, Bal M, Chiosea SI, Dahlstrom JE, Kakkar A, Kiss K, Laco J, Mittal N, Pasricha S, Samra S, Zidar N, Bullock M, Chernock R, Faquin W, Richardson MS, Hayes DN, Huang SH, Yang J, Alsugair Z, Benzerdjeb N, Chou S, Cooper C, Dimnik K, Dutta R, Gomez RS, Hernandez-Prera JC, Kamboj M, Agander TK, Kumar A, Lee JTH, Bell DM, Nagao T, Nakaguro M, Onyuma T, Park JH, Park JW, Patil A, Podhola M, Rane S, Rasmussen SA, Rozko, Shah P, Sharma D, Stefi S, Stubsgaard A, Tetzner AC, Wenig BM, Westra WH, Wise L, Yoon SO, HN-CLEAR steering committee and clinical advisory group. PMID: 41449157 [PubMed - indexed for MEDLINE]
	The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. Lancet Oncol Neoptolemos JP, Springfeld C, Öhlund D, Büchler MW, Michalski CW. PMID: 41449156 [PubMed - in process]
	A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment. Lancet Oncol Gerritsen JKW, Karschnia P, Bello L, Hervey-Jumper S, Young JS, Seidel K, Satoer DD, Schnell O, Parsons M, Nahed BV, Menna G, Teske N, External Rater Panel, Smith TR, Sanai N, Krieg SM, Schucht P, Broekman MLD, De Vleeschouwer S, Jakola AS, van den Bent MJ, Chang SM, Vogelbaum MA, Vincent AJPE, Tonn JC, Berger MS. PMID: 41449155 [PubMed - indexed for MEDLINE]
	A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making. Lancet Oncol Gerritsen JKW, Karschnia P, Bello L, Hervey-Jumper S, Young JS, Seidel K, Satoer DD, Schnell O, Parsons M, Nahed BV, Menna G, Teske N, External Rater Panel, Smith TR, Sanai N, Krieg SM, Schucht P, Broekman MLD, De Vleeschouwer S, Jakola AS, van den Bent MJ, Chang SM, Vogelbaum MA, Vincent AJPE, Tonn JC, Berger MS. PMID: 41449153 [PubMed - indexed for MEDLINE]
	First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial. Lancet Oncol Sun JM, Chao Y, Kim SB, Rha SY, Evans TRJ, Strickland AH, Wainberg Z, Chau I, Pelles-Avraham S, Ajani J, Malhotra R, Liu Q, Li S, Cha E, Kalaitzidou M, Huang X, Allen S, Hsu CH. PMID: 41449151 [PubMed - indexed for MEDLINE]
	Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial. Lancet Oncol Fizazi K, Saad F, Alonso-Gordoa T, , Barthélémy P, Voog E, Javier Cutuli H, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhöfer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK. PMID: 41449150 [PubMed - indexed for MEDLINE]
	Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study. Lancet Oncol Montagna G, Alvarado M, Myers S, Mrdutt MM, Sun SX, Sevilimedu V, Barrio AV, van den Bruele AB, Boughey JC, Boyle MK, Crown A, Kesmodel SB, King TA, Kuerer HM, Leisha EC, Moo TA, Weiss A, Williams AD, Parmar P, Diskin B, Hlavin C, Diego EJ, Polidorio N, Abdelwahab K, Banys-Paluchowski M, Kurzeder C, Heidinger M, Goldschmidt M, Schulz A, Heil J, Karadeniz Cakmak G, Pislar N, Riis M, Prakash I, Ovalle V, Ugurlu MU, Franceschini G, Sergeevich EA, Morales J, Lee HB, Galimberti V, Ahn SG, Ryu JM, Muslumanoglu M, Cab, Yoo TR, Vrancken Peeters MJ, Ferrucci M, Morrow M, Weber WP, microNAC Study Group. PMID: 41449148 [PubMed - indexed for MEDLINE]
	Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial. Lancet Oncol van den Bent MJ, Ghisai SA, Wick W, Sanson M, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Tabouret E, Gill S, Griffin M, Taal W, Rudà R, Weller M, McBain C, Reijneveld JC, Enting RH, Tran S, Lesimple T, Kocher M, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Hoogstrate Y, Nuyens S, Golfinopoulos V, Tesileanu CMS, Gorlia T, French P, Baumert BG. PMID: 41449147 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 1897372

Page 1 of 94869



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy